‘Alflorex®’ is a new once daily PrecisionBiotic® supplement based on the science of a patented and well documented and unique bacterial culture Bifidobacterium infantis 35624 (B. infantis35624). Bifidobacteria species are known for generations for their health promoting properties. B. infantis 35624 is an elite and natural bifidobacterium, a precision culture (PrecisionBiotic®), which has been specifically selected to work where it is needed.
B. infantis 35624 is backed by over 15 years of research and 50 publications in leading scientific journals and was originally researched and co-developed by Scientists, Clinicians and Gastroenterologists in Alimentary Health and the Alimentary Pharmabiotic Centre at University College Cork (one of the world’s leading centres in gut health research). The clinical trials in support of this PrecisionBiotic® were conducted in subjects suffering from a range of digestive problems including, bloating, trapped wind and abdominal discomfort.
Now available over the counter in Ireland as a food supplement, ‘Alflorex®’ is to be found in pharmacies nationwide for the promotion of a healthy digestive balance.
Commenting about ‘Alflorex®’, Professor Eamonn Quigley, one of the early investigators and Chief of Division of Gastroenterology and Hepatology, Houston Methodist Hospital and Professor of Medicine, Weill Cornell College of Medicine, Houston, Texas, said:
“This is one of the few products which has been truly developed on a scientific basis and tested in high quality clinical studies.”
‘Alflorex®’ has been developed by Alimentary Health, an innovation leader in the development and commercialisation of precision cultures and pharmabiotic technologies specialising in strains for digestive issues. Alimentary Health’s new and breakthrough scientific research is recognised as being at the cutting edge of discovery and application. This research is demonstrating that a new generation of elite and natural cultures can be selected to address specific issues rather than simply relying on the generalised effect of conventional ingredients. These ‘PrecisionBiotics®’ achieve a superior level of efficacy in a so-called ‘smart’ or targeted action to deliver benefit where it is needed.
Digestive discomfort is believed to affect up to 30% of the population, mostly young women between the ages of 25 and 55. Severe and long term digestive problems are responsible for a significant number of absences from work – on average 8.5 – 21.6 days per year*. Suffers report real and substantial impact on their daily lives. There are currently few management regimes available to help sufferers cope with symptoms.